Gossamer Bio (NASDAQ:GOSS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Gossamer Bio (NASDAQ:GOSS) to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Other analysts have also recently issued research reports about the company. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a research report on Tuesday, July 28th. HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Finally, Weiss Ratings upgraded shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Gossamer Bio has a consensus rating of “Hold” and an average price target of $256.00.

Gossamer Bio Trading Down 0.3%

Shares of GOSS opened at $10.70 on Friday. Gossamer Bio has a twelve month low of $9.10 and a twelve month high of $309.60. The firm has a market capitalization of $31.35 million, a P/E ratio of -0.19 and a beta of 2.00. The firm’s 50-day moving average is $13.34 and its two-hundred day moving average is $20.99.

Institutional Trading of Gossamer Bio

A number of hedge funds have recently added to or reduced their stakes in GOSS. Kalehua Capital Management LLC purchased a new position in shares of Gossamer Bio during the 1st quarter worth about $3,363,000. Corient Private Wealth LP acquired a new position in Gossamer Bio during the second quarter worth approximately $926,000. Hhlr Advisors LTD. acquired a new position in Gossamer Bio during the second quarter worth approximately $819,000. GSA Capital Partners LLP purchased a new position in Gossamer Bio during the second quarter worth approximately $2,467,000. Finally, Corient Private Wealth LLC raised its stake in Gossamer Bio by 19,123.7% during the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after purchasing an additional 3,825,879 shares during the period. 81.23% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.